MoonLake Immunotherapeutics
MLTX
MLTX
118 hedge funds and large institutions have $3.21B invested in MoonLake Immunotherapeutics in 2023 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
23.14% less ownership
Funds ownership: 128.44% → 105.3% (-23%)
91% less call options, than puts
Call options by funds: $5.47M | Put options by funds: $61.8M
Holders
118
Holding in Top 10
10
Calls
$5.47M
Puts
$61.8M
Top Buyers
| 1 | +$33.1M | |
| 2 | +$21.7M | |
| 3 | +$21.5M | |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$16.7M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$15.7M |
Top Sellers
| 1 | -$38.6M | |
| 2 | -$32.6M | |
| 3 | -$20.9M | |
| 4 |
AG
Artal Group
Luxembourg
|
-$20.4M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$18.9M |